| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.23 | 1e-09 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.21 | 7e-09 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-08 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-06 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.18 | 7e-06 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | 0.17 | 7e-06 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.29 | 1e-05 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | -0.15 | 4e-05 |
| mRNA | tubastatin A | CTRPv2 | pan-cancer | AAC | 0.22 | 4e-05 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.22 | 5e-05 |